Briefing
Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).
Baseline MRD was detected in 5/112 (4%) on osimertinib vs 13/108 (12%) on placebo; 4 of 5 became MRD-negative on osimertinib vs 0 of 13 on placebo. On-treatment MRD detection had 65% clinical sensitivity and 95% specificity for DFS events and preceded a DFS event by a median of 4.7 months. At 36 months, MRD/DFS event-free rates were 86% vs 36% (HR 0.23, 95% CI 0.15-0.36). Most MRD/DFS events on osimertinib occurred after treatment completion (19/28), 11 of those 19 within 12 months of stopping.
- n: 245 of 682 randomized patients had samples to produce MRD panels; 220 (32%) were evaluable (112 osimertinib, 108 placebo)
- Assay: RaDaR (NeoGenomics), personalized panels of up to 50 tumor-specific variants from whole-exome sequencing of resected tumor